MOMENTA PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2001-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.momentapharma.com
An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
- First Posted Date
- 2019-03-29
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT03896295
- Locations
- 🇬🇧
Momenta Investigational Site, Sheffield, United Kingdom
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03866577
- Locations
- 🇵🇱
Samodzielny Publiczny Szpital Kliniczny Nr 1, Lublin, Poland
🇺🇸University of Southern California, Los Angeles, California, United States
🇧🇪Ucl de Mont-Godinne, Yvoir, Belgium
A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT03772587
- Locations
- 🇬🇧
Momenta Investigational Site, Southampton, United Kingdom
Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2017-10-24
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 243
- Registration Number
- NCT02923583
- Locations
- 🇬🇧
Covance Clincal Research Unit Ltd, Leeds, United Kingdom
🇬🇧Hammersmith Medicines Research (HMR), London, United Kingdom
An Ascending Dose Study to Evaluate M281 Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2019-10-14
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02828046
- Locations
- 🇳🇱
PRA Health Sciences, Zuidlaren, Netherlands
Usability of an AI for M923 in Subjects With Moderate to Severe RA
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT02722044
- Locations
- 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
🇺🇸Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
🇺🇸Altoona Center for Clinical Research, PC, Duncansville, Pennsylvania, United States
Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 603
- Registration Number
- NCT02675023
- Locations
- 🇬🇧
QLON Phase 1 Clinic, London, United Kingdom
🇺🇸QOPK Phase 1 Clinic, Overland Park, Kansas, United States
Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 572
- Registration Number
- NCT02581345
- Locations
- 🇧🇬
DCC Sveti Georgi EOOD, Haskovo, Bulgaria
🇨🇦The Centre for Dermatology, Richmond Hill, Ontario, Canada
🇨🇦London Road Diagnostic Clinic and Medical Centre, Sarnia, Ontario, Canada
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT01621243
- Locations
- 🇺🇸
Metro-Minnesota Community Clinical Oncology Program, Saint Louis Park, Minnesota, United States
🇺🇸Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸University of New Mexico Cancer Center, Albuquerque, New Mexico, United States
Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 503
- Registration Number
- NCT00543400
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
🇨🇦University of Ottawa Heart Institute, Ottawa, Ontario, Canada